Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
trending now
trending in pharma/biotech
trending in device
pharmagather
advertise
Legal Help
login/register
You are here
Home
»
companies
» ALKS-5461
ALKS-5461
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Alkermes
FDA
advisory panels
ALKS-5461
major depressive disorder
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Alkermes
ALKS-5461
major depressive disorder
FDA
Flag link:
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
Alkermes
ALKS-5461
Flag link:
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Alkermes
JNJ
ALKS-5461
esketamine
major depressive disorder
Flag link:
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
TheStreet.com
FDA
drug approvals
Alkermes
ALKS-5461
CytRx
aldoxorubicin
Dynavax Technologies
HEPLISAV-B
Intra-Cellular Therapies
ITI-007
Novan
SB204
Portola Pharmaceuticals
betrixaban
PTC Therapeutics
ataluren
Rigel Pharmaceuticals
fostamatinib
TG Therapeutics
ublituximab
Flag link:
Alkermes slammed as top depression drug fails two PhIIIs
Alkermes slammed as top depression drug fails two PhIIIs
Fierce Biotech
Alkermes
ALKS-5461
clinical depression
clinical trials
Flag link:
